SCHEMBL21422282

SCHEMBL21422282

CCN(CC)CCCC(=O)I

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APOBEC3A P31941 1/20 0.47
APOBEC3G Q9HC16 1/20 0.47
PAOX Q6QHF9 1/20 0.44
ALDH1A1 P00352 2/20 0.39
NPSR1 Q6W5P4 1/20 0.37
KDM5A P29375 1/20 0.37
KDM4C Q9H3R0 1/20 0.37
GAA P10253 1/20 0.37
LMNA P02545 3/20 0.36
CA12 O43570 2/20 0.34
CA1 P00915 2/20 0.34
CA9 Q16790 2/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
MAOB P27338 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
BCHE P06276 1/20 0.33
ACHE P22303 1/20 0.33
MAPT P10636 1/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21422281 0.85 PAOX (0.38) APOBEC3AAPOBEC3GPAOXALDH1A1GAA
SCHEMBL1147864 0.80 PAOX (0.47) APOBEC3AAPOBEC3GPAOXALDH1A1NPSR1
SCHEMBL164414 0.78 PAOX (0.66) APOBEC3AAPOBEC3GPAOXALDH1A1NPSR1
SCHEMBL177754 0.78 NPSR1 (0.47) APOBEC3AAPOBEC3GPAOXALDH1A1NPSR1
SCHEMBL149151 0.78 AKR1B1 (0.50) PAOXALDH1A1KDM5AKDM4CLMNA
SCHEMBL21391387 0.76 PAOX (0.44) APOBEC3AAPOBEC3GPAOXALDH1A1NPSR1
Hydrochloric Acid SCHEMBL9078509 0.76 KDM5A (0.49) PAOXALDH1A1KDM5AKDM4CLMNA
SCHEMBL3933480 0.76 PAOX (0.44) APOBEC3AAPOBEC3GPAOXALDH1A1NPSR1
SCHEMBL25529753 0.76 ALDH1A1 (0.54) APOBEC3AAPOBEC3GPAOXALDH1A1NPSR1
SCHEMBL26353796 0.76 APOBEC3A (0.47) APOBEC3AAPOBEC3GPAOXALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190298681-A1 Nanoliposomal Targeting of Ephrin Receptor A2 (Epha2) and Related Diagnostics MERRIMACK PHARMACEUTICALS, INC. 2019-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190298681-A1 Nanoliposomal Targeting of Ephrin Receptor A2 (Epha2) and Related Diagnostics EPHA2, EPHB2, EPHB1 APOBEC3A 3448/4885APOBEC3G 3251/4885PAOX 3191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.